Zealand Pharma (ZEAL) Morgan Stanley 24th Annual Global Healthcare Conference summary

Strategic vision and ambitions

• Aims to become a leader in metabolic health with the Metabolic Frontier 2030 plan, targeting five marketed products and ten clinical programs by 2030.

• Focuses on addressing obesity and its related health consequences, emphasizing patient-centric solutions that improve health span and quality of life.

• Plans significant investment in research, with $800 million allocated over the next four to five years and expansion into new modalities and geographies, including a new research site in Cambridge, Massachusetts.

• Seeks to leverage data, AI, and innovative go-to-market strategies to reach patients more effectively in a rapidly evolving healthcare landscape.

• Envisions a fully integrated commercial presence to support launches and address the growing global burden of metabolic diseases.

Obesity portfolio and clinical progress

• Petrelintide, an amylin-based therapy, demonstrated double-digit weight loss with placebo-like tolerability in phase II, positioning it as a first-choice treatment for obesity.

• Phase III trials for petrelintide are launching in partnership with Roche, with a focus on rapid market entry and defining the amylin class.

• Combination therapy (ZINERGI trial) with Roche aims to optimize the balance between efficacy and tolerability, targeting patients needing additional weight loss or with comorbidities.

• Survodutide, partnered with Boehringer, is advancing through phase III with promising data on weight loss and metabolic health, particularly reducing liver and visceral fat.

• Survodutide's development includes multiple indications such as obesity, type 2 diabetes, MASH/NASH, and heart failure, with key data readouts expected through 2027.

Rare disease and pipeline expansion

• Dasiglucagon is in late-stage development for congenital hyperinsulinism, with FDA resubmission planned and partnership discussions ongoing to maximize patient reach.

• Glepaglutide for short bowel syndrome is in a second phase III trial for US approval, with an EU decision expected soon; partnerships are sought for commercialization.

• Early-stage pipeline includes a Kv1.3 blocker for autoimmune diseases, with phase I/II studies underway and plans to partner for broader development.

• Research efforts are expanding beyond peptides into new modalities and partnerships, aiming for a robust pipeline of clinical assets.

• Strategic focus remains on innovation and partnerships to drive future growth and address unmet needs in metabolic and rare diseases.